Alpine Immune Sciences to Present at 2018 Wedbush PacGrow Healthcare Conference

Alpine Immune Sciences, Inc. ALPN, a company focused on discovering and developing innovative immunotherapies to treat cancer, autoimmune/inflammatory, and other diseases, today announced the company will present a business overview and update at the 2018 Wedbush PacGrow Healthcare Conference on Tuesday, August 14, 2018 at 3:40 pm Eastern Time in New York, NY.

A live webcast of the presentation will be available online in the investor relations section of the company's website at https://ir.alpineimmunesciences.com/events. A replay of the presentation will be available on the company website for 90 days following the webcast.

About Alpine Immune Sciences, Inc.

Alpine Immune Sciences, Inc. is focused on developing novel protein-based immunotherapies using its proprietary Variant Ig Domain (vIgD) technology. Our scientific platform is designed to interact with multiple targets, including many present in the immune synapse. Alpine's vIgDs are developed using a process known as directed evolution, which produces proteins capable of either enhancing or diminishing an immune response and thereby may potentially apply therapeutically to cancer, autoimmune, and inflammatory diseases. Alpine has also developed Transmembrane Immunomodulatory Protein (TIP) technology, based on the vIgD technology, to potentially enhance engineered cellular therapies. For more information, visit www.alpineimmunesciences.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180806005529/en/